Primary prevention of coronary heart disease: Guidance from Framingham: A statement for healthcare professionals from the AHA task force on risk reduction

Circulation

Volumn 97, Issue 18, 1998, Pages 1876-1887

  Grundy, Scott M ^a   Balady, Gary J ^a   Criqui, Michael H ^a   Fletcher, Gerald ^a   Greenland, Philip ^a   Hiratzka, Loren F ^a   Houston Miller, Nancy ^a   Kris Etherton, Penny ^a   Krumholz, Harlan M ^a   LaRosa, John ^a   Ockene, Ira S ^a   Pearson, Thomas A ^a   Reed, James ^a   Washington, Reginald ^a   Smith Jr , Sidney C ^a  

^a AMERICAN HEART ASSOCIATION   (United States)

Author keywords

AHA Medical Scientific Statements; Coronary disease; Prevention; Risk factors

Indexed keywords

BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETES MELLITUS; FAMILY HISTORY; HEALTH PRACTITIONER; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; OBESITY; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; UNITED STATES;

EID: 0032510662     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.18.1876     Document Type: Review

References (175)

1. Kannel WB. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol. 1988;62:1109-1112.
2. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 1993;269:3015-3023.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1329-1445.
4. Joint National Committee. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md: National Heart, Lung, and Blood Institute; 1993:49. NIH publication No. 93-1088.
5. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md: National Heart, Lung, and Blood Institute; 1997. NIH publication No. 98-4080.
6. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary risk using risk factor categories. Circulation. In press.
7. Doyle JT, Dawber TR, Kannel WB, Heslin AS, Kahn HA. Cigarette smoking and coronary heart disease: combined experience of the Albany and Framingham studies. N Engl J Med. 1988;266:796-801.
8. Kannel WB. Cigarette smoking and coronary heart disease. Ann Intern Med. 1964;60:1103-1106.
9. Kannel WB, Shurtleff D. The Framingham Study: cigarettes and the development of intermittent claudication. Geriatrics. 1973;28:61-68.
10. Gordon T, Kannel WB, McGee D, Dawber TR. Death and coronary attacks in men after giving up cigarette smoking: a report from the Framingham Study. Lancet. 1974;2:1345-1348.
11. Kannel WB. Hypertension, blood lipids, and cigarette smoking as co-risk factors for coronary heart disease. Ann N Y Acad Sci. 1978;304: 128-139.
12. Castelli WP, Garrison RJ, Dawber TR, McNamara PM, Feinleib M, Kannel WB. The filter cigarette and coronary heart disease: the Framingham story. Lancet. 1981;2:109-113.
13. Hubert HB, Holford TR, Kannel WB. Clinical characteristics and cigarette smoking in relation to prognosis of angina pectoris in Framingham. Am J Epidemiol. 1982;115:231-242.
14. Garrison RJ, Feinleib M, Castelli WP, McNamara PM. Cigarette smoking as a confounder of the relationship between relative weight and long-term mortality: the Framingham Heart Study. JAMA. 1983;249: 2199-2203.
15. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med. 1985;313:1038-1043.
16. Kannel WB, McGee DL, Castelli WP. Latest perspectives on cigarette smoking and cardiovascular disease: the Framingham Study. J Card Rehabil. 1984;4:267-277.
17. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J. 1987;113:1006-1010.
18. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA. 1988;259:1025-1029.
19. Sortie PD, Kannel WB. A description of cigarette smoking cessation and resumption in the Framingham Study. Prev Med. 1990;19:335-345.
20. Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension: the Framingham Study. Ann Intern Med. 1967;67:48-59.
21. Kannel WB, Oral contraceptive hypertension and thromboembolism. Int J Gynaecol Obstet. 1979;16:466-472.
22. Kannel WB, Sortie P, Gordon T. Labile hypertension: a faulty concept? The Framingham Study. Circulation. 1980;61:1183-1187.
23. Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension: the Framingham Study. Circulation. 1980;61:1179-1182.
24. Shea S, Cook EF, Kannel WB, Goldman L. Treatment of hypertension and its effect on cardiovascular risk factors: data from the Framingham Heart Study. Circulation. 1985;71:22-30.
25. Kannel WB, Dannenberg AL, Abbott RD. Unrecognized myocardial infarction and hypertension: the Framingham Study. Am Heart J. 1985; 109:581-585.
26. Harris T, Cook EF, Kannel W, Schatzkin A, Goldman L. Blood pressure experience and risk of cardiovascular disease in the elderly. Hypertension. 1985;7:118-124.
27. Castelli WP, Anderson K. A population at risk: prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 1986;80:23-32.
28. Garrison RJ, Kannel WB, Stokes J III, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987;16:235-251.
29. Dannenberg AL, Kannel WB. Remission of hypertension: the 'natural' history of blood pressure treatment in the Framingham Study. JAMA. 1987;257:1477-1483.
30. Dannenberg AL, Garrison RJ, Kannel WB. Incidence of hypertension in the Framingham Study. Am J Public Health. 1988;78:676-679.
31. Kannel WB, Higgins M. Smoking and hypertension as predictors of cardiovascular risk in population study. J Hypertens. 1990;8:53-58.
32. Kannel WB, Zhang T, Garrison RJ. Is obesity-related hypertension less of a cardiovascular risk? The Framingham Study. Am Heart J. 1990; 120:1195-1201.
33. Leitschuh M, Cupples LA, Kannel W, Gagnon D, Chobanian A. High-normal blood pressure progression to hypertension in the Framingham Heart Study. Hypertension. 1991;17:22-27.
34. Thomas HE Jr, Kannel WB, Dawber TR, McNamara PM. Cholesterolphospholipid ratio in the prediction of coronary heart disease: the Framingham Study. N Engl J Med. 1966;274:701-705.
35. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study. Ann Intern Med. 1971;74:1-12.
36. Kannel WB. The role of cholesterol in coronary atherogenesis: the Framingham Study. Med Clin North Am. 1974;58:363-377.
37. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study. Ann Intern Med. 1979;90:85-91.
38. Garrison RJ, Castelli WP, Feinleib M, Kannel WB, Havlik RJ, Padgett SJ, McNamara PM. The association of total cholesterol, triglycerides, and plasma lipoprotein cholesterol levels in first-degree relatives and spouse pairs. Am J Epidemiol. 1979;110:313-321.
39. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol. 1980; 46:649-654.
40. Garrison RJ, Wilson PW, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham Offspring Study. Metabolism. 1980;29:1053-1060.
41. Abbott RD, Garrison RJ, Wilson PWF, Castelli WP. Coronary heart disease risk: the importance of joint relationships among cholesterol levels in individual lipoprotein classes. Prev Med. 1982;11:131-141.
42. Kannel WB, Gordon T. The search for an optimum serum cholesterol. Lancet. 1982;2:374-375.
43. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation. 1983;67: 730-734.
44. Wilson PW, Garrison RJ, Abbott RD, Castelli WP. Factors associated with lipoprotein cholesterol levels: the Framingham Study. Arteriosclerosis. 1983;3:273-281.
45. Gordon T, Kannel WB. Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. Am Heart J. 1982;103:1031-1039.
46. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256:2835-2838.
47. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA. 1987;257:2176-2180.
48. Kannel WB. Cholesterol and risk of coronary heart disease and mortality in men. Clin Chem. 1988;34:B53-B59.
49. Wilson PW, Christiansen JC, Anderson KM, Kannel WB. Impact of national guidelines for cholesterol risk factor screening: the Framingham Offspring Study. JAMA. 1989;262:41-44.
50. McNamara JR, Cohn JS, Wilson PW, Schaefer EJ. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem. 1990;36:36-42.
51. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High-density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707-714.
52. Castelli WP, Doyle JT, Gordon T, Harnes CG, Hjortland MC, Hulley SB, Kagan A, Zukel WJ. HDL cholesterol and other lipids in coronary heart disease: the Cooperative Lipoprotein Phenotyping Study. Circulation. 1977;55:767-772.
53. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: the Framingham Study. Arteriosclerosis. 1988;8:207-211.
54. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality: the Framingham Heart Study. Arteriosclerosis. 1988;8:737-741.
55. Gordon DJ, Probstfield JL, Garrison RJ, Neaton ID, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
56. Schaefer EJ, Moussa PB, Wilson PW, McGee D, Dallai G, Castelli WP. Plasma lipoproteins in healthy octogenarians: lack of reduced high density lipoprotein cholesterol levels: results from the Framingham Heart Study. Metabolism. 1989;38:293-296.
57. Wilson PW. High-density lipoprotein, low-density lipoprotein, and coronary artery disease. Am J Cardiol. 1990;66:7A-10A.
58. Garcia M, McNamara P, Gordon T, Kannel WB. Cardiovascular complications in diabetics. Adv Metab Disord. 1973;2(suppl 2):493-499.
59. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population 16-year follow-up study. Diabetes. 1974;23:105-111.
60. Kannel WB, Seidman JM, Fercho W, Castelli WP. Vital capacity and congestive heart failure: the Framingham Study. Circulation. 1974;49: 1160-1166.
61. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women: the Framingham Study. Ann Intern Med. 1977;87: 393-397.
62. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation. 1979;59:8-13.
63. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care. 1979; 2:120-126.
64. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA. 1979;241:2035-2038.
65. Wilson PW, Anderson KM, Kannel WB. Epidemiology of diabetes mellitus in the elderly: the Framingham Study. Am J Med. 1986;80:3-9.
66. Kannel WB, Garrison RJ, Wilson PWF. Obesity and nutrition in elderly diabetic patients. Am J Med. 1986;80:22-30.
67. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women: the Framingham Study. JAMA. 1988;260:3456-3460.
68. Podgor MJ, Kannel WB, Cassel GH, Sperduto RD. Lens changes and the incidence of cardiovascular events among persons with diabetes. Am Heart J. 1989;117:642-648.
69. Brand FN, Abbott RD, Kannel WB. Diabetes, intermittent claudication, and risk of cardiovascular events: the Framingham Study. Diabetes. 1989;38:504-509.
70. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990;120:672-676.
71. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Predicting coronary heart disease in middle-aged and older persons: the Framingham Study. JAMA. 1977;238:497-499.
72. Kannel WB, Gordon T. Evaluation of cardiovascular risk in the elderly: the Framingham Study. Bull N Y Acad Med. 1978;54:573-591.
73. Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB. Coronary risk associated with age and sex of parental heart disease in the Framingham Study. Am J Cardiol. 1989;64:555-559.
74. Dannenberg AL, Levy D, Garrison RJ. Impact of age on echocardiographic left ventricular mass in a healthy population (the Framingham Study). Am J Cardiol. 1989;64:1066-1068.
75. D'Agostino RB, Kannel WB, Belanger AJ, Sytkowski PA. Trends in CHD and risk factors at age 55-64 in the Framingham Study. Int J Epidemiol. 1989;18(suppl 1):S67-S72.
76. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67: 968-977.
77. Higgins M, Kannel W, Garrison R, Pinsky J, Stokes J III. Hazards of obesity: the Framingham experience. Acta Med Scand. 1988;723:23-36.
78. Kannel WB, Cupples LA. Cardiovascular and noncardiovascular consequences of obesity. In: Stunkard AJ, Baum A, eds. Perspectives in Behavioral Medicine: Eating, Sleeping, and Sex. Hillsdale, NJ: Lawrence Erlbaum Associates Inc; 1989:109-129.
79. Kannel WB, Sorlie P. Some health benefits of physical activity: the Framingham Study. Arch Intern Med. 1979;139:857-861.
80. Kannel WB, Wilson P, Blair SN. Epidemiological assessment of the role of physical activity and fitness in development of cardiovascular disease. Am Heart J. 1985;109:876-885.
81. Kannel WB, Belanger A, D'Agostino R, Israel I. Physical activity and physical demand on the job and risk of cardiovascular disease and death: the Framingham Study. Am Heart J. 1986;112:820-825.
82. Dannenberg AL, Keller JB, Wilson PW, Castelli WP. Leisure time physical activity in the Framingham Offspring Study: description, seasonal variation, and risk factor correlates. Am J Epidemiol. 1989;129: 76-88.
83. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Washington R, Smith SC Jr, for the American Heart Association Science Advisory and Coordinating Committee. Guide to primary prevention of cardiovascular diseases: a statement for healthcare professionals from the Task Force on Risk Reduction. Circulation. 1997;95:2329-2331.
84. Myers RH, Kiely DK, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J. 1990;120:963-969.
85. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991;11:2-14.
86. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med. 1980;302:1383-1389.
87. Schaefer EJ, Levy RI, Anderson DW, Danner RN, Brewer HB Jr, Blackwelder WC. Plasma triglycerides in regulation of HDL-cholesterol levels. Lancet. 1978;2:391-393.
88. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J. 1986;112:432-437.
89. Hodis HN, Mack WJ, Dunn M, Liu C-R, Liu C-H, Selzer RH, Krauss RM. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 1997;95:2022-2026.
90. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
91. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
92. Lamarche B, Tchemof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Small, dense low density lipoprotein phenotype as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1996;94:69-75.
93. Grundy SM, Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1-4.
94. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis. 1994;108:111-126.
95. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol, and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994;24:444-453.
96. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994;271:999-1003.
97. Bostom AG, Cupples A, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA. 1996;276:544-548.
98. Ridker PM. Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270: 2195-2199.
99. Moliterno DJ, Jokinen EV, Miserez AR, Lange RA.,Willard JE, Boerwinkle E, Hillis LD, Hobbs HH. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol. 1995;15:850-855.
100. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
101. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;322:1549-1554.
102. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258: 1183-1186.
103. Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease studies. Circulation. 1991;83:836-844.
104. Lee AJ, Lowe GD, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J. 1993;69:338-342.
105. Ernst E. Fibrinogen as a cardiovascular risk factor-interrelationship with infections and inflammation. Eur Heart J. 1993;14(suppl K):82-87.
106. Scarabin P-Y, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc G, Evans AE, Samama MM, Cambien F. Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction: the ECTIM Study. Arterioscler Thromb. 1993;13:886-891.
107. Herren T, Stricker H, Haeberli A, Do DD, Straub PW. Fibrin formation and degradation in patients with arteriosclerotic disease. Circulation. 1994;90:2679-2686.
108. Meade TW, North WR, Chakrabarti R, Haines AP, Stirling Y, Thompson SG, Brozovic M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980;1:1050-1054.
109. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
110. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
111. Miller GJ, Cruickshank JK, Ellis LJ, Thompson RL, Wilkes HC, Stirling Y, Mitropoulos KA, Allison JV, Fox TE, Walker AO. Fat consumption and factor VII coagulant activity in middle-aged men: an association between a dietary and thrombogenic coronary risk factor. Atherosclerosis. 1989;78:19-24.
112. Gram J, Jespersen J. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarction. Thromb Haemost. 1987;57: 137-139.
113. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
114. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991;12:157-161.
115. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J. 1990;11: 525-528.
116. Reaven GM. Insulin resistance and its consequences: non-insulin dependent diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus. Philadelphia, Pa: Lippincott-Raven Publishers; 1996:509-519.
117. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationship of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest. 1995;96:88-98.
118. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis. 1975;22:215-227.
119. Genest J Jr, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cordial. 1990;16:1114-1119.
120. Genest JJ Jr, McNamara JR, Upson B, Salem DN, Ordovas JM, Schaefer EJ, Malinow MR. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb. 1991; 11:1129-1136.
121. Israelsson B, Brattstrom LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis. 1988;71:227-233.
122. Stampfer MJ, Malinow MR, Willen WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
123. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991;48:536-545.
124. Kluijtmans LA, van den Heuvel LP, Boers GH, Fresst P, Stevens EM, van Oost BA, den Heijer M, Trijbels FJ, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
125. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking: a preliminary report. JAMA. 1990;264:3018-3024.
126. McGill HC Jr, McMahan A, Malcom GT, Oalmann MC, Strong JP, for the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. Arterioscler Thromb Vasc Biol. 1997;17:95-106.
127. Stamler J, Wentworth D, Neaton ID. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256: 2823-2828.
128. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(suppl II):II-38-II-46.
129. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
130. Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med. 1985;313:1511-1514.
131. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
132. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
133. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
134. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease, Pan 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
135. Kaplan N. Meta-analysis of hypertension treatment trials. Lancet. 1990; 335:1093.
136. Moser M, Hebert P, Hennekens CH. An overview of the meta-analyses of the hypertension treatment trials. Arch Intern Med. 1991;151: 1277-1279.
137. Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York City, NY: Raven Press Publishers; 1995:253-270.
138. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP, for the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 1995;15:431-440.
139. National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 1995. NIH publication No. 95-1468.
140. Klag MJ, Ford DE, Mead LA, He J. Whelton PK, Liang KY, Levine DM. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993;328:313-318.
141. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. Br Med J. 1994;308:363-366.
142. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J. 1994;308:367-373.
143. Cleeman JI, Grundy SM. National Cholesterol Education Program recommendations for cholesterol testing in young adults: a science-based approach. Circulation. 1997;95:1646-1650.
144. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults, Part 1. Ann Intern Med. 1996;124:515-517.
145. Garber AM, Browner WS. Cholesterol screening guidelines: consensus, evidence, and common sense. Circulation. 1997;95:1642-1645.
146. Smith SC, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Could KL, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
147. Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Ann Intern Med. 1990;112:780-792.
148. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
149. Strong JP, Richards ML. Cigarette smoking and atherosclerosis in autopsied men. Atherosclerosis. 1976;23:451-476.
150. Solberg LA, Strong JP. Risk factors and atherosclerotic lesions: a review of autopsy studies. Arteriosclerosis. 1983;3:187-198.
151. Kannel WB. Cigarette smoking and peripheral arterial disease. Prim Cardiol. 1986;12:13-17.
152. US Department of Health and Human Services. Reducing the Health Consequences of Smoking: 25 Years of Progress. A Report of the Surgeon General. Washington, DC: US Government Printing Office; 1989. DHHS publication No. DCD 89-8411.
153. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey. 1988-1991. Hypertension. 1995;25:305-313.
154. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Diseases. New York City, NY: McGraw-Hill Publishing Co; 1995:1981-2030.
155. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
156. Rubin EM, Krauss RM, Spangler AE, Verstuyft JG, Gift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1993;385:265-267.
157. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein AI gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;31:9607-9611.
158. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PW. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res. 1994;35: 871-882.
159. Karbapas P, Hilkki M, Laakso M. Isolated low HDL cholesterol, an insulin-resistant state. Diabetes. 1994;3:411-417.
160. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med. 1994;154:73-82.
161. Martin-Jadraque R, Tato F, Mostaza JM, Vega GL, Grundy SM. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. Arch Intern Med. 1996;156: 1081-1088.
162. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
163. ADA Consensus Panel. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes. 1993;2: 434-444.
164. Wingard DL, Barren-Connor E. Heart disease and diabetes. In: Diabetes in America. 2nd ed. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 1995:429-448. NIH publication No. 95-1468.
165. Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ, Barlow GK, Stephenson SH, Lalouel JM, Kuida H. Familial dyslipidemic hypertension: evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA. 1988;259:3579-3586.
166. Working Group Report on Management of Patients with Hypertension and High Blood Cholesterol. Bethesda, Md: US Dept of Health and Human Services; National Heart, Lung, and Blood Institute; 1990. NIH publication No. 90-2361.
167. Epstein FH, Ostrander LD Jr, Johnson BC, Payne MW, Hayner NS, Keller JB, Francis T Jr. Epidemiological studies of cardiovascular disease in a total community - Tecumseh, Michigan. Ann Intern Med. 1965;62:1170-1187.
168. Paul O, Lepper MH, Phelan WH, Dupertuis GW, MacMillan A, McKean H, Park H. A longitudinal study of coronary heart disease. Circulation. 1963;28:20-31.
169. Stamler J, Lindberg HA, Berkson DM, Shaffer A, Miller W, Poindexter A. Prevalence and incidence of coronary heart disease in strata of the labor force of a Chicago industrial corporation. J Chronic Dis. 1960; 11:405-420.
170. Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chronic Dis. 1978;31:201-306.
171. Goldbourt U, Holtzman E, Neufeld HN. Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. Br Med J. 1985;290:1239-1243.
172. Keys A. Coronary heart disease in seven countries. Circulation. 1970; 41(suppl I):I-1-I-211.
173. Marmot MG, Syme SL, Kagan A, Kato H, Cohen JB, Belsky J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: prevalence of coronary and hypertensive heart disease and associated risk factors. Am J Epidemiol. 1975;102:514-525.
174. Worth RM, Kato H, Rhoads GG, Kagan K, Syme SL. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: mortality. Am J Epidemiol. 1975;102: 481-490.
175. Fraser GE. Determinants of ischemic heart disease in Seventh-Day Adventisls: a review. Am J Clin Nutr. 1988;48:833-836.